secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001171843-26-002720
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass reports tovecimig hits PFS endpoint in BTC Ph2/3; plans BLA submission
------------------------------------------------------------------------------

- Tovecimig + paclitaxel met key secondary PFS endpoint: median 4.7 vs 2.6 months (HR=0.44, p<0.0001).
- Primary ORR (previously announced) was 17.1% vs 5.3% (p=0.031); one complete response in tovecimig arm.
- OS endpoint not met due to 54% crossover; ITT OS 8.9 vs 9.4 months (HR=1.05, p=0.78).
- Crossover patients had median OS 12.8 months vs 6.1 months for non-crossover (HR=0.54, p=0.04).
- Company intends to meet with FDA to discuss data in advance of a planned BLA submission for second-line BTC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/0001171843-26-002720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326002720/f8k_042526.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-002720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer